Neulasta (Pegfilgrastim)

Neulasta (pegfilgrastim) is a myeloid growth factor used to manage neutrophil deficiency associated with chemotherapy and stem cell collection.

• Chemotherapy‑induced neutropenia: reduces the incidence and duration of severe neutropenia in patients receiving myelosuppressive chemotherapy.
• Stem cell mobilization for transplantation: enhances peripheral blood progenitor cell collection in donors prior to autologous or allogeneic stem cell transplantation.

• Pegfilgrastim is a recombinant pegylated form of granulocyte colony‑stimulating factor. After subcutaneous injection it binds with high affinity to the G‑CSF receptor on neutrophil precursors in the bone marrow, activating intracellular JAK/STAT signaling. This stimulates proliferation, differentiation and activation of neutrophil lineage cells, leading to an increased absolute neutrophil count and accelerated recovery from chemotherapy‑induced myelosuppression.

Neulasta may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Bone pain: mild to moderate discomfort in bones or joints.
• Injection site reactions: redness, swelling or itching at the injection site.
• Headache: transient mild headache.
• Fatigue: feeling unusually tired.

Serious or Rare Side Effects

• Splenic rupture: rare but potentially life‑threatening.
• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Leukocytosis: excessively high white blood cell count.

Neulasta requires careful clinical consideration before use.

• Assess baseline neutrophil count: verify patient’s absolute neutrophil count before administration.
• Avoid concurrent myelosuppressive agents: do not give with other drugs that further suppress bone marrow.
• Monitor for bone pain: provide analgesics as needed.
• Use caution in patients with splenic disorders: increased risk of splenic complications.
• Pregnancy and breastfeeding: safety not established; weigh benefits versus risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neulasta can interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid)

• Live vaccines: may increase infection risk; avoid within two weeks of administration.
• Other G‑CSF products: additive effects on neutrophil counts; avoid simultaneous use.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may reduce efficacy; monitor neutrophil response.
• Chemotherapy agents: schedule timing to avoid overlapping peaks; monitor blood counts.
• Anticoagulants: rare reports of bleeding; observe for signs of hemorrhage.